Angiofollicular Lymph Hyperplasia

Angiofollicular lymph hyperplasia (angiofollicular lymph node hyperplasia) is a rare disease where one or more lymph nodes grow too much and become abnormally large. “Lymph” refers to the lymphatic system, which is part of your immune system. “Follicular” refers to small round areas inside the lymph node where immune cells grow. “Hyperplasia” means there are more cells than normal.

Angiofollicular lymph node hyperplasia, also called Castleman disease, is a rare disorder where lymph nodes grow in an abnormal, tumor-like way and release too many inflammatory proteins such as interleukin-6 (IL-6). This extra inflammation can cause fever, weight loss, tiredness, night sweats, anemia, and organ enlargement. Treatments focus on shrinking or removing the abnormal lymph node tissue, blocking IL-6 and other immune signals, and preventing complications like infections or organ damage.

In this disease, the lymph node structure becomes thick, crowded, and full of extra blood vessels and immune cells (B cells and plasma cells). The growth is non-cancerous (benign), but it can still cause serious problems because of inflammation and pressure on nearby organs.Cancer.gov+2NCBI+2

Doctors now usually use the name Castleman disease for this condition. It is considered a lymphoproliferative disorder, meaning the lymph tissue is growing more than it should, but it is not exactly a typical cancer. It can affect just one lymph node group (often in the chest or abdomen), or many groups throughout the body.NCBI+2Wikipedia+2

When only one area is involved, many people have no symptoms and the disease is found by chance on a scan. When many lymph nodes and tissues in the body are involved, people may have fever, weight loss, tiredness, enlarged liver or spleen, and blood test changes due to strong inflammation.Wikipedia+2Cureus+2

---

Other names

Angiofollicular lymph hyperplasia is known by several different names in the medical literature. All of the names below refer to the same general group of conditions, unless otherwise stated:

1. Castleman disease – the most widely used modern name.

2. Angiofollicular lymph node hyperplasia – a classic name that describes what the lymph node looks like under the microscope.Cancer.gov+1

3. Angiofollicular lymphoid hyperplasia – a similar phrase emphasizing lymphoid (immune) tissue.ScienceDirect

4. Giant lymph node hyperplasia – stresses the large size of the lymph nodes.Wikipedia+1

5. Lymphoid hamartoma – “hamartoma” means an overgrowth of normal tissue in an abnormal arrangement.

6. Castleman tumor – sometimes used when there is a single mass that looks like a tumor, although it is not a true cancer.Wikipedia+1

Different authors and hospitals may prefer different names, but the underlying concept is the same: non-cancerous overgrowth of lymph node tissue with typical blood vessel and follicle changes.

---

Types of angiofollicular lymph hyperplasia

Doctors classify this disease in several ways. Understanding the main types helps to explain causes, symptoms, and treatment.

Types by number of lymph node areas (clinical types)

1. Unicentric Castleman disease (UCD)
   In unicentric disease, only one lymph node region (for example, one cluster in the chest, neck, or abdomen) is affected. The enlarged node often forms a single, well-defined mass. Many people have no symptoms, and the disease is found on a scan done for another reason. Surgery to remove the mass often cures this form.NCBI+2Autoimmune Association+2

2. Multicentric Castleman disease (MCD)
   In multicentric disease, many lymph node regions and sometimes spleen, liver, and bone marrow are involved. This form causes systemic inflammation, fever, weight loss, night sweats, fatigue, and abnormal blood tests. Multicentric Castleman disease is not one single disease; it has subtypes with different causes and treatments.NCBI+2Wikipedia+2

Types by cause in multicentric disease

Multicentric Castleman disease (MCD) is divided into three main cause-based types:

1. HHV-8–associated MCD
   This type is clearly linked to infection with human herpesvirus 8 (HHV-8), the same virus that can cause Kaposi sarcoma. It is most common in people with weakened immune systems, especially people living with HIV. The virus drives very high levels of inflammatory proteins (like interleukin-6, IL-6), causing fever, enlarged nodes, and organ problems.ASH Publications+2Rare Awareness Rare Education Portal+2

2. Idiopathic multicentric Castleman disease (iMCD)
   “Idiopathic” means the cause is unknown. This type occurs without HHV-8 infection, but still shows strong inflammation and Castleman-type lymph node changes. Many patients have very high IL-6 levels and abnormal immune activation. Researchers think immune dysregulation or autoimmunity may play a key role.ASH Publications+2NCBI+2

3. MCD with associated disorders (e.g., POEMS)
   Some patients have multicentric Castleman disease together with POEMS syndrome (a rare disease involving neuropathy, abnormal proteins, and endocrine problems) or other blood disorders. In these cases, Castleman disease is part of a wider complex of illnesses.Cleveland Clinic+2ASH Publications+2

Types by microscopic (histologic) appearance

Under the microscope, lymph node tissue from angiofollicular lymph hyperplasia falls into several patterns:NCBI+2Wikipedia+2

1. Hyaline-vascular type
   This is the most common pattern in unicentric disease. The lymph node shows many small follicles with shrunken centers, thick “onion-skin” layers of lymphocytes around them, and many small blood vessels with glassy (hyaline) walls.

2. Plasma cell type
   This type has more active germinal centers and sheets of plasma cells in the spaces between follicles. It is more often associated with multicentric disease and strong systemic inflammation.

3. Mixed type
   Some lymph nodes show features of both hyaline-vascular and plasma cell types.

4. HHV-8–associated pattern
   In HHV-8–positive MCD, pathologists can see viral protein in certain lymphoid cells. The architecture often resembles plasmacytic or hypervascular types, with strong vascular and plasma cell changes.NCBI+1

---

Causes and contributing factors

The exact cause of angiofollicular lymph hyperplasia is not fully known in many patients, especially in idiopathic unicentric and idiopathic multicentric forms. However, research has found several known causes and likely contributing factors. Below, each item is explained in simple terms. Where evidence is weaker, you’ll see phrases like “may contribute” or “is thought to.”

1. Human herpesvirus 8 (HHV-8) infection
   HHV-8 is a virus that infects lymphoid cells. In HHV-8–associated multicentric Castleman disease, the virus is a proven driver: it infects cells, increases viral and human IL-6 production, and triggers massive immune activation and lymph node growth.ASH Publications+2Rare Awareness Rare Education Portal+2

2. HIV infection and immune deficiency
   People living with HIV are more likely to have HHV-8 infection, and their weakened immune system allows the virus to multiply and drive Castleman disease. HIV itself does not directly “cause” Castleman disease, but it strongly increases the risk of HHV-8–associated MCD.Wikipedia+1

3. Overproduction of interleukin-6 (IL-6)
   IL-6 is a signaling protein (cytokine) that promotes inflammation, B-cell growth, and acute-phase responses. Many patients with Castleman disease, including iMCD, have very high IL-6 levels. This overproduction is believed to be a central driver of fever, anemia, fatigue, high CRP, and lymph node overgrowth.NCBI+2ASH Publications+2

4. Other cytokine storms and immune dysregulation
   In addition to IL-6, other cytokines such as VEGF, IL-1, and TNF-α may be elevated. This abnormal network of signals keeps the immune system constantly “switched on,” leading to chronic inflammation and tissue growth.NCBI+1

5. Idiopathic immune activation (unknown trigger)
   In idiopathic multicentric Castleman disease (iMCD), no virus or clear external cause is found. The immune system appears to attack or activate itself without a clear reason. This is sometimes compared to autoimmune or autoinflammatory diseases.ASH Publications+1

6. Genetic or molecular predisposition (suspected)
   A small number of cases show somatic mutations or abnormal signaling pathways in immune cells, suggesting that genetic or molecular changes may predispose some people to develop this disorder. Current evidence is limited, but this is a focus of ongoing research.NCBI+1

7. Chronic antigenic stimulation
   Long-term exposure to antigens (foreign or abnormal proteins) may drive constant immune activation in lymph nodes. Chronic infections or environmental exposures may cause this, although specific antigens are usually not identified.eurorad.org+1

8. Chronic inflammatory diseases (e.g., Crohn’s disease, sarcoidosis)
   Some reports suggest that long-standing inflammatory diseases such as Crohn’s disease or sarcoidosis can be associated with angiofollicular lymph node hyperplasia. The persistent inflammation may “overstimulate” the lymphoid tissue, leading to hyperplasia.Medicover Hospitals

9. Autoimmune disorders
   Autoimmune diseases involve misdirected immune attacks against the body’s own tissues. Autoimmune conditions sometimes coexist with Castleman disease, and similar immune pathways (e.g., IL-6) are involved. This suggests that autoimmune mechanisms may contribute in some patients.NCBI+1

10. POEMS syndrome
    POEMS is a rare disorder with neuropathy, organ enlargement, monoclonal plasma cells, and skin changes. Many POEMS patients also have Castleman-type lymph node changes. In such cases, the same abnormal plasma cells and cytokines may drive both diseases.Cleveland Clinic+1

11. Plasma cell dyscrasias and monoclonal gammopathy
    Abnormal clones of plasma cells, even without full-blown myeloma, can produce excessive antibodies and cytokines that may contribute to Castleman-like lymph node changes and systemic inflammation.NCBI+2ASH Publications+2

12. Immunosuppressive medications or organ transplant status
    Patients who take strong immune-suppressing drugs after an organ transplant or for autoimmune disease may develop HHV-8 infection and MCD because their immune system cannot control the virus.Rare Awareness Rare Education Portal+1

13. Co-existing Kaposi sarcoma
    Kaposi sarcoma, also caused by HHV-8, frequently occurs in patients with HHV-8–associated MCD. The shared virus and cytokine environment suggest overlapping mechanisms that can drive both diseases.Wikipedia+1

14. Chronic viral infections other than HHV-8 (possible)
    Some patients with iMCD have evidence of other chronic viral infections. While these viruses are not proven direct causes, they may provide ongoing antigen stimulation or immune activation.ScienceDirect+1

15. Chronic bacterial infections (possible)
    Long-term bacterial infections, especially those affecting the lungs or gut, may lead to continuous stimulation of the immune system and enlargement of lymph nodes. Evidence is mostly from case reports.eurorad.org+1

16. Developmental abnormality of lymphoid tissue
    Some authors have proposed that unusual development of lymphoid tissue (a kind of structural abnormality or hamartoma) could set the stage for the characteristic overgrowth seen in Castleman disease.eurorad.org+1

17. Elevated vascular endothelial growth factor (VEGF)
    VEGF is a protein that promotes new blood vessel formation. High VEGF levels are found in many patients with Castleman disease, especially those with POEMS. VEGF may contribute to the rich blood vessel network seen in angiofollicular hyperplasia and to swelling, edema, and fluid buildup.NCBI+1

18. Bone marrow involvement and dysregulated hematopoiesis
    In some cases, bone marrow shows reactive changes or marrow failure. Abnormal signaling between bone marrow and lymph nodes may help sustain the disease process.ScienceDirect+1

19. Environmental or unknown triggers
    For many patients, no clear infection, autoimmune disease, or genetic change is found. Environmental or unknown triggers may start an abnormal immune response that later becomes self-sustaining.

20. Combination of factors (multifactorial model)
    In reality, many patients probably have more than one contributing factor: for example, genetic susceptibility plus HHV-8 infection plus immune suppression. Current research supports a multifactorial model rather than a single universal cause.NCBI+2ASH Publications+2

---

Symptoms and signs

Symptoms vary a lot between unicentric and multicentric disease. Unicentric disease may cause no symptoms. Multicentric disease often causes strong inflammatory symptoms. Below are 15 important symptoms or signs, each explained in simple English.Medscape+4Wikipedia+4Cureus+4

1. Enlarged lymph nodes
   The most basic sign is one or more enlarged lymph nodes. In unicentric disease, there may be a single mass in the chest, neck, or abdomen. In multicentric disease, many nodes in different regions become enlarged. They may be felt as lumps under the skin or seen on imaging scans.

2. Fever
   Many patients with multicentric disease have repeated or continuous fevers. This is due to high levels of IL-6 and other cytokines that reset the body’s temperature control as if there is a serious infection, even when no infection is present.

3. Night sweats
   Patients often wake up drenched in sweat, especially at night. This is another effect of strong inflammatory signals and fever-type responses in the body.

4. Unintended weight loss
   Weight loss can occur because chronic inflammation reduces appetite, increases energy use, and alters metabolism. Patients may eat normally but still lose weight.

5. Severe tiredness (fatigue)
   Fatigue is one of the most common complaints. Chronic inflammation, anemia, and cytokine effects on the brain all contribute. Patients may feel exhausted even after small efforts.

6. Loss of appetite and nausea
   Inflammatory cytokines and enlarged abdominal organs can lead to poor appetite, early fullness, or nausea. Patients may feel that they cannot finish normal meals.

7. Abdominal pain or fullness
   Enlarged lymph nodes in the abdomen, as well as an enlarged liver or spleen, can cause a feeling of fullness, pressure, or dull pain in the upper or lower abdomen.

8. Enlarged spleen (splenomegaly)
   The spleen can become enlarged due to increased immune cell activity and blood cell turnover. This may cause a feeling of heaviness in the left upper abdomen and may contribute to low blood counts.

9. Enlarged liver (hepatomegaly)
   The liver may also enlarge. This can be detected by a doctor during examination or on ultrasound and sometimes causes right-sided upper abdominal discomfort.

10. Swelling in the legs, abdomen, or around the lungs
    Some patients develop fluid buildup (edema in the legs, ascites in the abdomen, or pleural effusion around the lungs). VEGF and cytokines increase vascular permeability, so fluid leaks out of blood vessels into body spaces.

11. Shortness of breath or cough
    A large lymph node mass in the chest, or fluid around the lungs, can compress airways or limit lung expansion, leading to cough and breathlessness, especially on exertion.

12. Frequent infections
    Despite an overactive immune system, patients may have low functional immune protection and abnormal antibody patterns, which can increase the risk of infections.

13. Skin changes
    Some patients, especially with HHV-8–associated or POEMS-associated forms, may develop skin lesions such as small vascular spots, thickening, or darkened areas. Kaposi sarcoma lesions may also appear in HHV-8–positive patients.

14. Enlarged or painful tonsils and oral lesions
    Because lymphoid tissue is everywhere in the body, including in the throat, some patients may have enlarged tonsils or other masses in the mouth or neck area.

15. Neurologic symptoms (in POEMS or severe inflammation)
    In POEMS-associated cases, nerve damage can cause weakness, numbness, tingling, or difficulty walking. Severe systemic disease can also cause confusion or concentration problems due to chronic illness.

---

Diagnostic tests

Diagnosing angiofollicular lymph hyperplasia / Castleman disease requires a combination of history, physical exam, blood tests, imaging, and, most importantly, a lymph node biopsy. Below are 20 key tests, grouped by category.Wikipedia+5NCBI+5ScienceDirect+5

Physical exam tests (bedside observations)

1. General physical examination and vital signs
   The doctor checks temperature, pulse, blood pressure, breathing rate, and overall appearance. Persistent fever, rapid heart rate, and signs of chronic illness (such as weight loss or pale skin) can suggest a systemic inflammatory process rather than a simple localized infection.

2. Palpation of lymph nodes
   The doctor feels the neck, armpits, groin, and other accessible areas for enlarged lymph nodes. In unicentric disease, there may be one large, well-defined node. In multicentric disease, many nodes may be slightly enlarged. The size, consistency, and mobility help distinguish this disease from lymphoma or simple infection.

3. Abdominal examination (liver and spleen)
   By gently pressing on the abdomen, the doctor can detect enlargement of the liver and spleen. A large firm edge of the liver or spleen below the ribs suggests organ involvement by the inflammatory process, which is common in multicentric Castleman disease.

4. Cardiovascular and lung examination
   Listening with a stethoscope can reveal fluid around the lungs (reduced breath sounds) or signs of heart strain. The doctor also looks for leg edema and jugular venous distension, which can suggest fluid overload or heart involvement due to chronic inflammation and anemia.

Manual / bedside clinical tests

5. Performance status assessment (e.g., ECOG scale)
   The doctor may rate how well the patient can perform daily activities (from fully active to bedridden). Poor performance status indicates a strong systemic impact of the disease and helps guide treatment choices and prognosis.

6. Palpation for edema and fluid
   The doctor presses on the legs, ankles, and abdomen to look for pitting edema or ascites (fluid in the abdomen). These findings suggest increased vascular permeability and protein leaks, which are typical in some forms of Castleman disease.

7. Basic neurologic examination
   Simple tests of muscle strength, reflexes, sensation, and walking are done at the bedside. Weakness, loss of reflexes, or numbness may point toward associated neuropathy, especially in POEMS-related cases or when treatments have affected the nerves.

Laboratory and pathological tests

8. Complete blood count (CBC) with differential
   A CBC looks at red cells, white cells, and platelets. Patients may have anemia (low red cells), low platelets, or abnormal white cell patterns, due to chronic inflammation, splenic sequestration, or bone marrow involvement. Elevated inflammatory markers in the white blood cell differential can also be seen.

9. Inflammatory markers: ESR and C-reactive protein (CRP)
   ESR and CRP are general tests of inflammation. They are often markedly elevated in active multicentric Castleman disease. High CRP (for example, >20 mg/L) is one of the criteria used to define active disease in some guidelines.Medscape+1

10. Liver and kidney function tests
    Blood tests such as AST, ALT, alkaline phosphatase, bilirubin, creatinine, and urea show whether the liver and kidneys are affected. Abnormal results may indicate organ damage from chronic inflammation, amyloid deposition, or side effects of treatment.

11. Serum protein electrophoresis and immunoglobulin levels
    These tests measure and separate the different proteins and antibodies in the blood. Many patients have increased immunoglobulins (hypergammaglobulinemia) or monoclonal proteins, especially in plasma cell or POEMS-related cases. This helps distinguish Castleman disease from simple infections.

12. Cytokine and VEGF levels (where available)
    Some specialized centers measure IL-6 and VEGF levels. Very high IL-6 supports a diagnosis of multicentric Castleman disease and helps explain the systemic symptoms. High VEGF may also suggest associated POEMS syndrome or strong vascular involvement.NCBI+2ASH Publications+2

13. Viral serologies: HIV and HHV-8 testing
    Blood tests for HIV and HHV-8 help determine whether the multicentric disease is HHV-8–associated or idiopathic. A positive HHV-8 test with compatible clinical and biopsy findings supports the diagnosis of HHV-8–associated MCD. HIV status is critical for prognosis and treatment planning.Wikipedia+2ASH Publications+2

14. Autoimmune and other screening tests
    Tests such as ANA, rheumatoid factor, complement levels, or others may be done to look for associated autoimmune diseases. Abnormal results can help identify overlapping conditions and guide treatment.

15. Lymph node excisional biopsy (gold standard)
    This is the key diagnostic test. A whole lymph node (or a large piece) is surgically removed and examined under the microscope. The pathologist looks for the classic features of angiofollicular hyperplasia: abnormal follicles, onion-skin mantle zones, many small blood vessels, and plasma cell or mixed patterns. The biopsy confirms Castleman-type histology and helps exclude lymphoma, metastatic cancer, or other causes.Archives of Medical Science+3NCBI+3PubMed+3

16. Immunohistochemistry and flow cytometry on lymph node tissue
    In addition to standard histology, the pathologist may use special stains (immunohistochemistry) to mark certain cell types and viral proteins (for example, HHV-8 LANA). Flow cytometry can check for clonal B-cell or T-cell populations that would suggest lymphoma. These tests support the diagnosis of Castleman disease and help rule out malignancy.NCBI+2Wikipedia+2

Electrodiagnostic tests

17. Electrocardiogram (ECG)
    An ECG records the electrical activity of the heart. It is not specific for Castleman disease but is important to check for heart strain, rhythm problems, or effects of anemia and fluid overload. This helps in assessing overall fitness and risks before major treatments such as surgery or chemotherapy.

18. Nerve conduction studies and electromyography (EMG)
    In patients with suspected POEMS syndrome or significant neuropathy, nerve conduction tests and EMG measure how well the nerves and muscles conduct electrical signals. They can show a length-dependent neuropathy, which may be part of the wider disease complex involving Castleman-type lymph node changes.Cleveland Clinic+1

Imaging tests

19. Ultrasound (US)
    Ultrasound is a simple, non-invasive scan that can detect enlarged lymph nodes in the neck, abdomen, or pelvis and assess liver and spleen size. Castleman masses often appear as solid, well-defined, hypoechoic nodules. Ultrasound can also guide needle biopsies in some locations.Archives of Medical Science+1

20. Computed tomography (CT), MRI, and PET-CT scans
    CT scans are widely used to map all enlarged lymph nodes in the chest, abdomen, and pelvis and to look for organ enlargement or fluid collections. MRI can be useful in certain areas (like the spine). PET-CT combines CT with a radioactive tracer to show metabolic activity; Castleman nodes typically show increased uptake. Imaging is essential for deciding whether the disease is unicentric or multicentric and for planning surgery or systemic therapy.jornaldepneumologia.com.br+3RSNA Publications+3ScienceDirect+3

Non-pharmacological (non-drug) treatments

1. Rest and energy management
People with Castleman disease often feel very tired because of chronic inflammation and anemia. Planning the day with regular rest periods, sitting instead of standing for long tasks, and asking for help with heavy work can reduce exhaustion and dizziness. Energy conservation helps patients keep strength for important activities and may lower the feeling of “crash” after over-doing things.

2. Gentle aerobic exercise
Short, light activities such as slow walking or stationary cycling can improve stamina, mood, and sleep over time. In cancer and chronic-illness research, supervised aerobic exercise has been shown to reduce fatigue and improve quality of life when started slowly and increased gradually. People should avoid exercising during fevers or severe flares and always follow their doctor’s advice about intensity.

3. Light resistance and strength training
Using light weights or resistance bands a few times per week can help maintain muscle mass, which often drops during chronic disease and treatment. Stronger muscles improve balance, walking, and ability to do daily tasks, and in cancer patients, better strength is linked with better survival. Any new strength program should be designed with a physiotherapist or trainer experienced with medically fragile patients.

4. Physical therapy
A physical therapist can test walking, balance, joint movement, and pain, then design safe exercises and stretching. For Castleman patients who have nerve pain, weakness, or stiffness from steroids or chemotherapy, an individualized program can reduce falls and improve independence. Therapy may also teach breathing exercises if there is chest discomfort or fluid.

5. Occupational therapy
Occupational therapists help people adapt home and work tasks when fatigue or weakness is a problem. Simple changes like using shower chairs, grab bars, long-handled tools, or pacing techniques can prevent accidents and maintain dignity. This support is especially important when Castleman disease causes chronic symptoms or after major surgery.

6. Nutrition counseling
A registered dietitian can plan meals high in protein, calories, vitamins, and minerals to fight weight loss, muscle wasting, and poor wound healing. During active disease or chemotherapy, eating several small, nutrient-dense meals may be easier than three big ones. Good nutrition supports immune function and overall quality of life.

7. Infection-prevention habits
Castleman disease itself and many treatments weaken the immune system, so careful hygiene is essential. Regular handwashing, mask use in high-risk settings, avoiding contact with sick people, and safe food handling can reduce serious infections. Doctors may also advise certain vaccines or prophylactic medicines as part of this prevention plan.

8. Stress-reduction and mindfulness
Chronic illness and uncertainty cause strong emotional stress, which can intensify fatigue and pain. Relaxation techniques such as slow breathing, guided imagery, meditation, or prayer can calm the nervous system and improve sleep and mood. Short daily practice works better than rare long sessions and is generally safe alongside medical treatment.

9. Psychological counseling and support groups
Talking with a psychologist, social worker, or counselor helps people process fear, anger, and sadness that come with a rare disease. Support groups (online or in person) allow patients and families to share experiences and coping tips. Better mental health is linked with better treatment adherence and overall well-being.

10. Sleep hygiene routines
Regular bedtimes, limiting screens before sleep, comfortable room temperature, and reducing caffeine later in the day can improve sleep quality. Poor sleep worsens pain, mood, and fatigue, so treating insomnia with behavioral methods is important before turning to sedating drugs. Deep breathing or short relaxation exercises before bed may help.

11. Smoking cessation
If the patient smokes, stopping is one of the most powerful ways to protect the lungs, blood vessels, and immune system. Smoking increases risk of infections, blood clots, and heart disease, which can worsen outcomes in Castleman disease and during chemotherapy. Nicotine replacement and counseling greatly increase quit success.

12. Limiting alcohol
Alcohol can irritate the liver and bone marrow and can interact with many medicines used in Castleman disease. Keeping intake very low or avoiding alcohol completely reduces the risk of liver injury, bleeding, and accidents. This is especially important in patients on chemotherapy, sirolimus, or other immunosuppressive drugs.

13. Vaccination planning
Inactivated vaccines (such as flu and many COVID-19 vaccines) may be recommended before or between treatments to prevent serious infections. Timing is important because some drugs reduce vaccine response, so the hematology team usually coordinates vaccinations with the treatment schedule. Live vaccines are often avoided in immunosuppressed patients.

14. Pain management with non-drug methods
Heat packs, cold packs, gentle stretching, massage by trained therapists, and relaxation exercises can reduce muscle and joint pain. These methods are especially useful when people want to limit strong pain medicines or already take many drugs. Always avoid deep or aggressive massage over enlarged lymph nodes or surgical areas.

15. Lymph-drainage and compression (with specialist guidance)
In some patients with limb swelling due to enlarged nodes or previous surgery, specially trained therapists may use gentle lymphatic drainage massage and compression garments. This can improve comfort and mobility. It must only be done under medical advice, to avoid problems when active inflammation or clots are present.

16. Careful sun-exposure and skin protection
Some drugs used in Castleman disease increase risk of skin cancer or make the skin more sensitive to sunlight. Using sunscreen, protective clothing, and avoiding tanning beds reduces long-term skin damage. Early evaluation of any new skin lesions is important.

17. Social and financial support services
Social workers and patient-advocacy groups can help with disability paperwork, treatment costs, and transport to hospital visits. Reducing financial stress helps families focus on treatment and recovery. This is often overlooked but can strongly affect adherence and well-being.

18. Palliative care (symptom-focused care)
Palliative care teams are experts in controlling pain, breathlessness, nausea, and emotional distress at any disease stage, not only at the end of life. In complex conditions like multicentric Castleman disease, early palliative care is linked with better symptoms and sometimes longer life. It complements, rather than replaces, active treatment.

19. Rehabilitation after surgery
When a large lymph node or group of nodes is removed, people may have pain, stiffness, or reduced range of motion. Early, gentle stretching and guided exercise after the surgeon’s approval helps restore movement and prevent long-term disability. Scar-care advice can also improve comfort and appearance. Pathology & Oncology Research

20. Education and written care plans
Clear written instructions about warning signs, medicines, lab tests, and follow-up visits help patients and families feel in control. Education about Castleman disease reduces fear and enables better shared decision-making with doctors. Many Castleman-focused organizations provide patient-friendly guides and treatment algorithms.

---

Drug treatments –

Only siltuximab is specifically FDA-approved for idiopathic multicentric Castleman disease in HIV-negative, HHV-8-negative adults. Most other drugs listed here are used off-label or as part of broader lymphoma/autoimmune regimens. Never start, stop, or change any of these without a specialist. FDA Access Data+1

1. Siltuximab (SYLVANT – IL-6 monoclonal antibody)
Siltuximab is a laboratory-made antibody that binds directly to interleukin-6, the key inflammatory messenger driving many symptoms of multicentric Castleman disease. The FDA label recommends 11 mg/kg as an intravenous infusion over about one hour every 3 weeks, adjusted by the treating team. Common side effects include infusion reactions, infections, low white cells, and abnormal liver tests, so regular blood monitoring is required. It is currently the only drug specifically approved in the US for idiopathic multicentric Castleman disease. PMC+3FDA Access Data+3FDA Access Data+3

2. Tocilizumab (ACTEMRA – IL-6 receptor antibody, off-label for CD)
Tocilizumab is an antibody that blocks the IL-6 receptor rather than IL-6 itself and is approved for conditions like rheumatoid arthritis and giant cell arteritis. In Castleman disease, especially when siltuximab is not available, tocilizumab may be used off-label to reduce inflammation and symptoms. Dosing is usually weight-based IV or subcutaneous on a schedule similar to its approved indications, and doctors watch for infections, low blood counts, and liver enzyme elevations. FDA Access Data+1

3. Rituximab (RITUXAN and biosimilars – anti-CD20 antibody)
Rituximab targets the CD20 protein on B-cells and is approved for several lymphomas and autoimmune diseases. In Castleman disease, especially HHV-8-associated or multicentric cases, rituximab can shrink abnormal lymph nodes and improve symptoms, often combined with steroids or chemotherapy. Typical lymphoma doses are 375 mg/m² IV on specific schedules, but exact dosing depends on regimen; serious side effects include infusion reactions, infections, and hepatitis B reactivation, so screening and close monitoring are essential. FDA Access Data+1

4. Corticosteroids (for example, prednisone)
Prednisone and similar steroids strongly suppress inflammation and are often used at the beginning of treatment or during flares in Castleman disease. They can quickly improve fever, appetite, and lymph node pain, and are sometimes combined with rituximab or chemotherapy. Long-term or high-dose use can cause weight gain, high blood sugar, osteoporosis, mood changes, and infection risk, so doctors aim to use the lowest effective dose and taper carefully.

5. CHOP-like chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
In aggressive or refractory multicentric Castleman disease, CHOP-based regimens—originally designed for lymphoma—may be used to kill abnormal lymphoid cells. Doses are calculated from body surface area and given as IV cycles every 3 weeks, with steroids taken orally or IV. Side effects can include hair loss, nausea, mouth sores, low blood counts, infection risk, and heart damage from doxorubicin; therefore, this approach is reserved for patients where benefits clearly outweigh risks.

6. Cyclophosphamide (alkylating agent)
Cyclophosphamide is a chemotherapy drug that damages DNA in rapidly dividing immune and cancer cells. In Castleman disease, it is usually part of combination regimens like CHOP rather than given alone. It can cause low blood counts, hair loss, nausea, and bladder irritation; patients are often advised to drink plenty of fluids and may receive medicines to protect the bladder.

7. Doxorubicin (anthracycline)
Doxorubicin interferes with DNA replication and is part of many lymphoma protocols. When used for Castleman disease within a combination regimen, it contributes to tumor shrinkage but carries a risk of heart damage at high cumulative doses. Doctors track heart function with echocardiograms and carefully limit total lifetime dose.

8. Vincristine (vinca alkaloid)
Vincristine blocks microtubules needed for cell division and is another CHOP component. It can help control disease but is well-known for causing nerve toxicity such as numbness, tingling, or weakness in hands and feet. Careful dosing and early reporting of symptoms help reduce long-term nerve damage.

9. Bortezomib (VELCADE and generics – proteasome inhibitor)
Bortezomib is a proteasome inhibitor approved for multiple myeloma and mantle-cell lymphoma. In Castleman disease, case series suggest it may help when disease is resistant to standard regimens, likely by inducing death of abnormal plasma cells that produce inflammatory cytokines. It is usually given as small IV or subcutaneous doses on a repeating schedule, and side effects can include neuropathy, low platelets, and infections. Thoracic Research and Practice

10. Thalidomide (THALOMID – immunomodulatory drug)
Thalidomide affects immune cell function and blood vessel growth and is approved for multiple myeloma. In some refractory Castleman cases, it has been used off-label to reduce symptoms and inflammatory markers, often with steroids or other agents. However, it carries major risks, including severe birth defects, blood clots, neuropathy, and sedation, so it is tightly controlled and absolutely contraindicated in pregnancy. Thoracic Research and Practice

11. Lenalidomide (REVLIMID – immunomodulatory drug)
Lenalidomide is a thalidomide analogue used for multiple myeloma and some lymphomas. It has been tried in small series of Castleman disease, often in patients who failed other treatments, to modulate immune pathways and reduce abnormal cell growth. It is taken orally in cycles; risks include severe birth defects, low blood counts, blood clots, and rash, and it is dispensed only through a strict safety program.

12. Sirolimus (RAPAMUNE – mTOR inhibitor)
Sirolimus blocks the mTOR pathway and is approved for preventing kidney-transplant rejection. In Castleman disease, particularly when IL-6–directed therapy fails, sirolimus has been used off-label to suppress abnormal immune activation and lymph node growth. It is taken orally with dose adjustments based on blood levels, and side effects include high cholesterol, mouth ulcers, impaired wound healing, and infection risk.

13. Interferon-alpha
Interferon-alpha is an immune-modulating cytokine used historically in some lymphoproliferative and viral diseases. In selected Castleman cases, especially when other options were limited, it has been used to slow disease activity and improve blood counts. Flu-like symptoms, depression, thyroid dysfunction, and cytopenias are common side effects, so it is less favored now that targeted antibodies are available.

14. Etoposide
Etoposide interferes with DNA topoisomerase II and is used in some aggressive lymphoma and hemophagocytic lymphohistiocytosis (HLH) regimens. Because Castleman disease can overlap with HLH-like inflammation, etoposide may appear in rescue protocols. It can cause profound bone-marrow suppression, hair loss, and nausea, so it is reserved for severe, life-threatening cases.

15. Antiviral therapy (e.g., ganciclovir for HHV-8)
When Castleman disease is associated with human herpesvirus-8, especially in people with HIV, antivirals such as ganciclovir or valganciclovir may be used alongside rituximab and ART to reduce viral activity. Doses follow HIV/CMV protocols and require kidney-dose adjustment. Side effects include bone-marrow suppression and kidney toxicity, so regular labs are required.

16. Antiretroviral therapy (ART) in HIV-associated disease
For patients with HIV-positive Castleman disease, modern ART is essential because controlling HIV helps control HHV-8 replication and immune over-activation. The specific drug combination is chosen by HIV specialists, and adherence is critical. Good HIV control can reduce relapses and improve survival alongside other Castleman-directed treatments.

17. Intravenous immunoglobulin (IVIG)
IVIG is pooled antibodies from healthy donors used to support immunity and modulate autoimmune reactions. In Castleman patients with recurrent infections or coexisting immune cytopenias, IVIG may be used to reduce infection frequency or stabilize blood counts. It is given as periodic IV infusions and can cause headache, infusion reactions, and rarely thrombosis or kidney injury.

18. Prophylactic antibiotics/antifungals
Some patients receiving strong immunosuppressive regimens are given low-dose antibiotics or antifungals to prevent opportunistic infections, such as Pneumocystis pneumonia. The exact drug, dose, and duration depend on the treatment regimen and blood counts. These medicines can have their own side effects (allergy, liver problems), so they are carefully individualized.

19. Supportive growth factors (e.g., G-CSF)
Granulocyte colony-stimulating factor (G-CSF) drugs such as filgrastim are sometimes used to raise white blood cell counts after chemotherapy, reducing infection risk. They are given as short courses of injections under the skin. Bone pain is a common side effect, and their use is tailored to the intensity of the chemotherapy regimen.

20. Proton-pump inhibitors and other supportive drugs
Because many Castleman therapies include steroids and chemotherapy, stomach-protective drugs, anti-nausea medicines, and drugs for blood pressure or blood sugar may be added. These do not treat Castleman disease directly but protect organs and improve tolerability of key therapies. Their exact choice and dose are customized by the treating team.

---

Dietary molecular supplements

Supplements can interact with chemotherapy or liver-acting drugs, so no supplement should be started without the hematologist’s approval.

1. Vitamin D
Vitamin D supports bone health and immune regulation. Many people with chronic illness have low levels, so doctors may recommend supplements if blood tests show deficiency. Typical replacement doses range from 800–2000 IU daily, but higher doses may be used short-term under supervision; excessive vitamin D can cause high calcium and kidney problems.

2. Omega-3 fatty acids (fish-oil)
Omega-3 fats from fish-oil capsules can help manage triglycerides, mild inflammation, and may support heart health. Common supplemental doses are 1–2 g per day of EPA+DHA, adjusted for bleeding risk and drug interactions. High doses can increase bleeding tendency, especially with aspirin, anticoagulants, or thrombocytopenia.

3. Probiotics
Probiotic capsules or yogurts contain beneficial bacteria that may help gut health, diarrhea, and antibiotic-related problems. In immunocompromised patients, only products suggested by the medical team should be used, and raw or unpasteurized preparations must be avoided. Evidence in cancer and hematology suggests modest benefits for some symptoms but not for curing the underlying disease.

4. Whey or plant protein powders
High-quality protein powders can help patients who struggle to meet protein needs through food alone because of poor appetite. A typical serving provides 15–25 g of protein once or twice daily, mixed with milk or plant drinks. People with kidney problems or specific dietary needs require individualized advice from a dietitian before using these products.

5. Multivitamin/mineral supplements
A standard once-daily multivitamin can cover basic micronutrient needs when intake is poor. Extra “mega-dose” formulas are usually unnecessary and can be harmful, particularly with iron, vitamin A, or vitamin E in high doses. Doctors may suggest special formulations if anemia or other deficiencies are present.

6. Vitamin B12 and folate (when deficient)
If blood tests show low B12 or folate and megaloblastic anemia, targeted supplements by mouth or injection can correct the deficiency and improve energy. Doses vary widely (e.g., B12 injections weekly then monthly) and must be guided by lab results. Supplementing without proven deficiency is usually not needed.

7. Zinc
Zinc is involved in immunity and wound healing. Short courses of low-to-moderate-dose zinc (for example, 10–25 mg/day) may be suggested in documented deficiency, but long-term high doses can cause copper deficiency and anemia. Any zinc plan should be coordinated with lab monitoring.

8. Selenium
Selenium is a trace element with antioxidant roles and thyroid involvement. Very small amounts are needed, and supplementation is usually limited to 50–100 micrograms per day when dietary intake is poor. High intake can be toxic, causing hair loss, gastrointestinal upset, and nerve problems.

9. Vitamin C (modest doses)
Vitamin C supports collagen synthesis and antioxidant defenses. In Castleman disease, low-to-moderate oral doses from diet and standard supplements (for example, 75–250 mg/day) are usually enough; very high “mega-dose” vitamin C or IV vitamin C for cancer is controversial and should not be used outside clinical trials.

10. Medical nutrition drinks
Ready-to-drink high-protein, high-calorie shakes are often easier than solid food when appetite is low. They supply carefully balanced macronutrients and micronutrients and can be sipped throughout the day. A dietitian can select lactose-free, low-sugar, or fiber-enriched formulas according to individual needs.

---

Immune-modulating / regenerative therapies

There are no true “stem-cell drugs” approved specifically for angiofollicular lymph node hyperplasia. Instead, doctors use immune-modulating biologics and, in rare cases, blood-stem-cell transplantation as procedures.

1. Hematopoietic stem-cell transplantation (HSCT – procedure, not a pill)
In very rare, life-threatening, treatment-resistant cases, autologous or allogeneic HSCT may be considered, especially if Castleman disease overlaps with other marrow disorders. High-dose chemotherapy wipes out diseased marrow, and donor or patient stem cells are infused to rebuild blood-forming tissue. This carries high risks of infection, graft-versus-host disease, and organ damage and is only done in specialized centers.

2. Siltuximab as a targeted immune-regenerative agent
By blocking IL-6, siltuximab often normalizes hemoglobin and inflammatory markers, helping the body restore more normal immune balance. Over months, this can feel like “regenerating” strength, although the drug is suppressing abnormal signals rather than boosting immunity. Response is tracked by symptoms, scans, and lab tests. PMC+2FDA Access Data+2

3. Tocilizumab (immune reset for IL-6 signalling)
Tocilizumab also interferes with IL-6 pathways at the receptor level, calming the overactive immune response in some patients not responding to siltuximab. With inflammation controlled, organs like the liver and bone marrow can recover function. The goal is immune balance, not general stimulation. FDA Access Data

4. Sirolimus (mTOR pathway modulation)
Sirolimus targets the mTOR pathway in lymphocytes and can dampen abnormal cell proliferation and cytokine release in difficult Castleman cases. Over time, this may reduce lymph-node size and allow more normal immune cell patterns, but it also increases infection risk, so blood counts and drug levels must be monitored.

5. Growth factors (e.g., G-CSF) after intensive therapy
G-CSF drugs like filgrastim stimulate bone-marrow stem and progenitor cells to produce more neutrophils after chemotherapy. They do not treat Castleman disease itself but help the marrow recover more quickly, reducing infection risk and hospital stays. Bone pain is a frequent, usually reversible side effect.

6. IVIG as immune modulation
In addition to helping fight infections, IVIG can modulate autoantibodies and inflammatory pathways. In some immune-overlap syndromes or severe infections, this can “rebalance” immune activity temporarily while other treatments work. Dosing is weight-based over several hours, and kidney function and fluid status must be watched.

---

Surgical treatments

1. Complete excision of a single affected lymph node (Unicentric Castleman disease)
For unicentric Castleman disease, removing the single abnormal lymph node with surgery is often curative. The surgeon carefully dissects the node away from nearby vessels and organs, usually under general anesthesia. After complete excision, many patients have no further disease and only need periodic check-ups. Dove Press+1

2. Regional lymph-node dissection when complete removal is difficult
If there are several nodes in one area (for example, chest or abdomen) but all in a block, surgeons may remove the whole package in one operation. This can reduce symptoms such as pain, pressure, or organ compression, and may be combined with later medical therapy. Risks depend on location and include bleeding, infection, and damage to nearby nerves or ducts. Pathology & Oncology Research

3. Minimally invasive (thoracoscopic or laparoscopic) lymph-node removal
In some patients, chest or abdominal nodes can be removed using keyhole surgery with a camera and small instruments. This approach may reduce pain, hospital stay, and scarring compared with open surgery, but is not suitable for very large or complex masses. The goal is the same: complete or near-complete removal of disease tissue. Pathology & Oncology Research

4. Debulking surgery for symptom relief
When complete cure is impossible because disease is multicentric, surgeons may still remove part of a large mass that compresses organs (such as bowel, lung, or kidney). This “debulking” can relieve pain, improve breathing or digestion, and make subsequent drug therapies safer. It is always weighed against operative risk and expected benefit. Dove Press+1

5. Diagnostic excisional biopsy
At first presentation, a surgical removal of a node for biopsy is often necessary to distinguish Castleman disease from lymphoma or other causes. Although this is mainly diagnostic, it sometimes also removes the entire diseased node in unicentric cases. Proper pathology is crucial to selecting the correct medical treatment plan. Pathology & Oncology Research

---

Prevention and risk-reduction

Castleman disease itself usually cannot be fully prevented, but complications can often be reduced:

1. Prompt treatment of infections – Seek medical care early for fevers, cough, urinary symptoms, or wounds to prevent sepsis.

2. Adherence to recommended therapy – Taking medicines on schedule and attending infusions improves disease control and lowers flare risk.

3. Regular follow-up visits and lab tests – Monitoring blood counts, liver and kidney function, and inflammatory markers helps detect relapse or toxicity early.

4. Vaccination according to specialist advice – Flu, COVID-19, and other inactivated vaccines reduce life-threatening infections.

5. Healthy lifestyle (no smoking, low alcohol) – Protects heart, lungs, and liver, which may be stressed by disease and drugs.

6. Safe food and water – Avoid raw or undercooked meat, unpasteurized milk, and unwashed produce to lower gastrointestinal infections.

7. Skin and catheter care – Good hygiene of central lines and surgical scars reduces bloodstream infections.

8. Bone-health protection – Adequate calcium/vitamin D, weight-bearing activity, and sometimes bone-protective drugs help counter long-term steroid use.

9. Sun protection when on photosensitizing or cancer-risk drugs – Lowers chance of skin cancers, especially with sirolimus or long-term immunosuppression.

10. Avoidance of unproven “miracle cures” – Extreme diets, coffee enemas, and unregulated “immune boosters” can delay real treatment and cause harm. Always discuss new therapies with the medical team first.

---

When to see a doctor urgently

People with angiofollicular lymph node hyperplasia should contact a doctor or go to emergency care immediately if they develop:

• High fever, chills, or feeling suddenly very unwell

• Shortness of breath, chest pain, or fast heartbeat

• Rapid swelling of lymph nodes, abdomen, or legs

• Confusion, severe headache, or extreme weakness

• Bleeding or bruising easily, or very dark/tarry stools

These may signal infection, severe anemia, bleeding, or disease flare and need fast assessment. Regularly scheduled visits with the hematologist/oncologist are also essential even when feeling well.

---

What to eat and what to avoid

1. Focus on varied, plant-rich meals
Emphasize fruits, vegetables of many colors, whole grains, beans, and nuts to supply vitamins, minerals, and fiber that support general health and bowel function.

2. Include enough protein at each meal
Eggs, dairy, lean meat, poultry, fish, tofu, or legumes help maintain muscle and immune proteins that may be lost during chronic inflammation.

3. Choose gentle, easy-to-digest foods on bad days
During flares or chemotherapy, soft foods like soups, yogurt, mashed potatoes, and smoothies may be easier to tolerate than heavy or spicy meals.

4. Eat small, frequent meals if appetite is low
Six to eight mini-meals or snacks can help meet calorie and protein needs without overwhelming the stomach.

5. Drink enough safe fluids
Water, soups, and oral nutrition drinks support circulation and kidney function, especially when fevers or diarrhea are present, unless fluid intake has been restricted by a doctor.

6. Avoid raw or undercooked animal products
Raw meat, fish (sushi), eggs, and unpasteurized dairy increase infection risk in immunosuppressed people and are best avoided.

7. Limit very salty or ultra-processed foods
Instant noodles, chips, processed meats, and very salty snacks can worsen blood pressure and fluid retention, especially in steroid-treated patients.

8. Be cautious with herbal products and “immune boosters”
Many herbal blends interact with chemotherapy or liver-metabolized drugs and may not be safe, even if “natural.” Always discuss with the medical team.

9. Limit sugary drinks and sweets
High sugar intake can worsen weight gain and blood-sugar problems from steroids and may displace more nutritious foods.

10. Moderate or avoid alcohol
Because many treatments stress the liver and bone marrow, it is usually safest to avoid or keep alcohol extremely low unless your doctor clearly says otherwise.

---

Frequently asked questions (15 FAQs)

1. Is angiofollicular lymph node hyperplasia the same as cancer?
Castleman disease behaves like a lymph-node tumor but is usually classified as a lymphoproliferative disorder, not a classic lymphoma. Some people with Castleman disease later develop lymphoma, so long-term follow-up is important.

2. Can unicentric Castleman disease be cured?
Yes, when there is only one affected lymph node, complete surgical removal often cures the disease, and many patients do not need further drug treatment. Regular check-ups are still advised. Dove Press+1

3. Is multicentric Castleman disease always fatal?
No. Outcomes have improved greatly with modern IL-6–targeted therapies like siltuximab and better supportive care, but multicentric disease is still serious and needs expert management. PMC

4. How long do I need to stay on siltuximab or other biologics?
Treatment length depends on response, side effects, and disease type. Many patients continue infusions every few weeks for years, with regular re-evaluation by their specialist. FDA Access Data+1

5. Will treatment affect my ability to work or study?
Fatigue, clinic visits, and side effects can reduce work or school capacity, especially at the beginning. Many people can return to at least part-time activities with good symptom control, workplace adjustments, and rehabilitation support.

6. Can I get pregnant or father a child after treatment?
Some therapies, including chemotherapy and thalidomide-like drugs, can harm fertility or cause severe birth defects. People considering pregnancy should talk with their team early about fertility preservation and safe timing; effective contraception is often required during and after certain medicines.

7. Do all Castleman patients need chemotherapy?
No. Many unicentric patients are cured with surgery alone. Others with multicentric disease may respond well to IL-6-targeted antibodies and steroids without classic cytotoxic chemotherapy. PMC

8. How is Castleman disease different from lymphoma?
Both can cause enlarged nodes, but Castleman disease has characteristic patterns of blood vessels and lymph-follicle changes under the microscope and often more cytokine-driven symptoms. Lymphoma typically shows clonal malignant cells and requires different chemotherapy. Pathology & Oncology Research

9. Which doctor should coordinate my care?
A hematologist/oncologist with experience in lymphoproliferative disorders usually leads care, often in connection with Castleman-focused centers or networks. They coordinate with surgeons, infectious-disease doctors, dietitians, and other specialists.

10. Are there clinical trials for Castleman disease?
Because it is rare, many advances come from clinical trials and registries. Patients can ask their doctors or Castleman foundations about ongoing studies of new antibodies, targeted drugs, and treatment strategies.

11. What lab tests are important to follow?
Commonly monitored tests include complete blood count, inflammatory markers (CRP, ESR), kidney and liver function, electrolytes, and sometimes viral loads in HHV-8-associated disease. Imaging (CT, PET-CT) may be repeated periodically. Pathology & Oncology Research

12. Can lifestyle alone control Castleman disease?
No. Lifestyle measures such as good nutrition, exercise, and stress management are helpful but cannot replace disease-directed medical treatment. Delaying proper therapy may allow serious complications to develop.

13. How often will I need scans?
Scan frequency depends on disease type, stage, and response to therapy. Many patients have imaging every 6–12 months after stabilization, but intervals may be shorter early in treatment or during flares. Pathology & Oncology Research

14. What is the long-term outlook?
Prognosis ranges from excellent in unicentric disease to variable in multicentric disease, depending on subtype, associated infections, and response to IL-6–targeted drugs. Early diagnosis and modern therapy have significantly improved survival in many series. PMC

15. What should I do next if I or a loved one has this diagnosis?
Work closely with a hematologist/oncologist familiar with Castleman disease, ask about your specific subtype and treatment options, and consider consultation with a specialized center or registry. Bring a written list of questions and medications to each visit to support shared decision-making.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 13, 2025.